Philipps Robert J, Lee Demler Tammie, Lee Claudia
University at Buffalo, School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Innov Clin Neurosci. 2012 Sep;9(9):14-7.
Proton pump inhibitors are among the world's most widely used therapeutic classes. Much of their use is attributed to their documented efficacy and apparent safety. For the most part, proton pump inhibitors are well tolerated with very few serious adverse events reported in the literature. Only a few previously identified case reports of severe neutropenia or agranulocytosis attributed to proton pump inhibitors use have been identified in the literature. However, agranulocytosis, neutropenia, and/or leukopenia are labeled as possible adverse events from post-marketing surveillance in the summary of product information for various proton pump inhibitors. In this report, we describe a case of probable omeprazole-induced blood dyscrasia in a clozapine-treated patient.
质子泵抑制剂是全球使用最广泛的治疗药物类别之一。它们的大量使用归因于已证实的疗效和明显的安全性。在很大程度上，质子泵抑制剂耐受性良好，文献中报道的严重不良事件极少。文献中仅发现少数先前确定的因使用质子泵抑制剂导致严重中性粒细胞减少或粒细胞缺乏症的病例报告。然而，在各种质子泵抑制剂的产品信息摘要中，粒细胞缺乏症、中性粒细胞减少症和/或白细胞减少症被列为上市后监测中可能出现的不良事件。在本报告中，我们描述了一例在接受氯氮平治疗的患者中可能由奥美拉唑引起的血液系统疾病的病例。
